ASX & MEDIA RELEASE **23 NOVEMBER 2017**

UPDATED TGA RULES ASSIST MEDICAL PRACTITIONER ACCESS TO MEDLAB'S CANNABIS PRODUCTS

- Recent changes to the TGA's Special Access Scheme make Medlab's cannabis medicines available based on specific needs
- Medical practitioners can prescribe Medlab's NanaBis™ (Cannabis CBD/THC pain product) and NanaBidial™ (Cannabis CBD seizure product) under TGA guidelines
- Medlab's Australian manufactured cannabis product expected to be available in late February 2018.
- Medlab allowed to import significantly larger annual volumes of cannabis

As medical life science company, Medlab Clinical Limited (ASX: MDC), prepares to commence its first clinical trial of a cannabis-based medicine shortly at the Royal North Shore Hospital, the Therapeutic Goods Administration (TGA) has announced changes to its Special Access Scheme to allow medical practitioners to use this type of cannabis medicine.

The effect of changes to the TGA's Special Access Scheme [2]is to make it easier for medical practitioners to prescribe cannabis-based medicines for patients in need, under certain conditions (see attached TGA flow chart).

This clinical trial of Medlab's cannabis-based medicine (NanaBis™) is understood to be the first of its kind in the world.

The clinical trial will take place at Royal North Shore Hospital in Sydney, under the supervision of Professor Stephen Clarke OAM, a medical oncologist, palliative medicine specialist and Professor of Medicine at the University of Sydney. Patients in the trial will be seriously ill oncology patients and would be administered NanaBis™ to assist pain management and in place of opioids.

Commentary

According to Medlab CEO, Sean Hall, continued support from the medical community and Therapeutic Goods Administration for cannabis-based medicine was pleasing.

"In pursuing a clinical trial route, we are seeking to make our medicines distinctive, giving medical practitioners, Government and industry stakeholders such as the Australian Medical Association (AMA) confidence in prescribing for our products," Sean Hall said.

AMA President, Dr Michael Gannon in March this year was quoted as saying "Show us the scientific evidence and doctors will prescribe it [cannabis]…"[1]

"The effect of the TGA changes[2] enable Medlab a faster route to commercialisation of our research," Sean Hall said.

---

1 https://ama.com.au/ausmed/green-light-medicinal-cannabis-ama-says-proceed-caution

2 https://www.tga.gov.au/sites/default/files/access-medicinal-cannabis-products-steps-using-access-schemes.pdf

Medlab has successfully renewed its Federal annual licences for continued importation of cannabis, allowing for significant increases in the amounts of cannabis allowed to be imported.

Medlab management estimates the annual finished product commercial value of its allowable importation of cannabis material to be approximately $30M AUD of what is an estimated Australian market of $250M.

According to Medlab CEO, Sean Hall the new licence was a significant step forward in Medlab's cannabis programme.

ISSUED FOR:	**MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co**
FOR FURTHER INFORMATION:	**SEAN HALL, CEO, MEDLAB CLINICAL** **TEL: +61 2 8203 9520, sean_hall@medlab.co**
ISSUED BY:	HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.

Access to medicinal cannabis products in Australia

Resource for doctors



Reference: Therapeutic Goods Association - https://www.tga.gov.au/sites/default/files/access-medicinal-cannabis-products-steps-using-access-schemes.pdf